Aspyra Announces Upgrade Agreements with LIS Customers
CALABASAS, Calif., Oct 13, 2008 (BUSINESS WIRE) — Aspyra, Inc. (AMEX:APY) announced today that the Company has entered into agreements with several customers to upgrade their existing Aspyra CyberLAB LIS system to the latest product release.
Aspyra customers that have recently signed upgrade agreements include:
Porter Hospital, Inc. (Middlebury, VT), Pathology & Clinical Laboratory Snd Bhd (Selangor, Malaysia), and IGeneX, Inc. (Palo Alto, CA), will be upgrading their existing Aspyra CyberLAB LIS’ to the current 7.2 version. Aspyra’s CyberLAB LIS is a scalable, feature-rich, and cost-effective LIS solution for hospital, clinic, and reference laboratory settings. CyberLAB 7.2 is available on a Windows platform, utilizing a MS SQL database structure. CyberLAB LIS features decision support tools with auto-verification, automated clinical reporting and multisite management.
“We continue to see an influx of activity within the laboratory marketplace. This is likely attributed to the dwindling population of medical technologists and the number of legacy systems in the marketplace, necessitating the need for improved productivity tools within the LIS. Aspyra continues to enhance our LIS with feature sets such as our decision support rules and automated reporting capabilities, that enable our customers to improve workflow and turnaround,” stated Michelle Del Guercio, Aspyra Director of Marketing and Product Management.
About Aspyra
Aspyra is a global provider of Health Care Information Technology (HCIT) solutions and services to the healthcare industry. The Company specializes in Clinical Information Systems (CIS), Picture Archive Communication Systems (PACS) and Clinical Image Management Systems (CIMS) for hospitals, multi-specialty clinics, clinical laboratories, imaging departments and centers and orthopedic environments. Aspyra’s highly scalable systems can be installed standalone or integrated to provide a single-vendor, enterprise-wide solution. For more information on Aspyra, its products and services, visit www.aspyra.com.
